As the effectiveness of beta-agonists for treating asthma attacks has been established, numerous other supportive treatments for asthma attacks have also been investigated, such as systemic glucocorticoids and magnesium. Among these additional therapies, inhaled furosemide is of particular interest; several studies have evaluated the effects of prophylactic inhaled furosemide in attenuating bronchoconstriction and asthma attacks. To determine the efficacy of inhaled furosemide during asthma attacks, we performed a systematic review using the MEDLINE, EMBASE, Web of Science, and Cochrane Library databases from their inception through 14 March 2014. A meta-analysis was conducted by calculating the standardized mean difference from each study and integrating these means using a random effects model. In addition, subanalyses were performed in the studies that evaluated the peak expiratory flow rate and the forced expiratory volume in 1 second.

We identified six studies using double-blinded, randomized control trial designs that evaluated inhaled furosemide in conjunction with standard treatments in patients experiencing asthma attacks \[[@CR1]-[@CR6]\] (Figure [1](#Fig1){ref-type="fig"}); a total of 78 patients received inhaled furosemide and 79 patients received a placebo (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). The mean age of patients ranged from 8.4 to 47 years \[[@CR3],[@CR6]\]. In two studies, patients were administered 40 mg inhaled furosemide \[[@CR1],[@CR2]\]; in one study, patients were administered 20 mg inhaled furosemide \[[@CR6]\]; and in the three studies that recruited children, patients were administered either 1.0 mg/kg \[[@CR4],[@CR5]\] or 10 mg/m^2^ \[[@CR3]\] inhaled furosemide.Figure 1**Study selection procedure.**Table 1**Trial characteristicsFurosemide groupPlacebo groupStudy (year)Number of randomized patientsNumber of patients completing studyMean patient age (years)Number of patients (male)Mean patient age (years)Number of patients (male)SmokingCOPDβ-agonist doseInhaled furosemide doseExpiratory airflow assessment time (minutes)Spirometry measurement usedSeverityHydrocortisone (mg)**Alshehri and colleagues, 2005 \[[@CR5]\]39398.419 (11)8.520 (9)N/A^a^N/A^a^0.15 mg/kg1.0 mg/kg30PEFR, FEV1.0ModerateN/AGonzález-Sánchez and colleagues, 2002 \[[@CR4]\]20209.810 (7)1010 (5)N/A^a^N/A^a^0.15 mg/kg1.0 mg/kg30, 60FEV1.0Mild or moderateN/ANannini and colleagues, 1992 \[[@CR1]\]2016317 (N/A)419 (N/A)N/AN/A2.5 mg40 mg15, 30PEFRN/AN/ANuhoğlu and colleagues, 2006 \[[@CR3]\]32328.616 (8)8.416 (12)N/A^a^N/A^a^0.15 mg/kg10 mg/m^2^N/APEFRMild or moderateN/AOno and colleagues, 1997^b^ \[[@CR6]\]37374720 (7)4117 (8)N/AExcludeN/A20 mg30, 60PEFR, FEV1.0Mild to severe100Pendino and colleagues, 1998^c^ \[[@CR2]\]4242386 (N/A)348 (N/A)Not \>10 pack-yearsExclude2.5 mg40 mg15, 30PEFRMild or moderate300COPD, chronic obstructive pulmonary disease; FEV1.0, forced expiratory volume in 1 second; N/A, not available; PEFR, peak expiratory flow rate. ^a^Smoking and COPD histories were not available, although no smoking or COPD history was assumed because patients were children. ^b^Combination treatment in all trials was simultaneous administration of a beta-agonist plus furosemide, except for Ono and colleagues, in which patients in both groups received hydrocortisone succinate and aminophylline, followed 30 minutes later by either furosemide or placebo. ^c^Only subgroup data (pertaining to patients whose exacerbations lasted \<8 hours) were available.Table 2**Trial resultsFurosemidePlaceboPEFRFEV1.0PEFRFEV 1.0Study (year)Baseline airflowSDPost-treatment airflowSDBaseline airflowSDPost-treatment airflowSDBaseline airflowSDPost-treatment airflowSDBaseline airflowSDPost-treatment airflowSD**Alshehri and colleagues, 2005 \[[@CR5]\]59.022.084.914.058.514.580.213.957.225.480.717.456.717.377.819.1Nuhoğlu and colleagues, 2006 \[[@CR3]\]17865.922266.1N/AN/A18351.721860.3N/AN/A**Baseline airflowSDNet airflow improvement above baselineSDBaseline airflowSDNet airflow improvement above baselineSDBaseline airflowSDNet airflow improvement above baselineSDBaseline airflowSDNet airflow improvement above baselineSD**González-Sánchez and colleagues, 2002 \[[@CR4]\]N/AN/A0.8200.4600.9100.067N/AN/A0.8500.3400.9800.078Nannini and colleagues, 1992 \[[@CR1]\]14768.026989.7N/AN/A23482.031656.2N/AN/AOno and colleagues, 1997 \[[@CR6]\]17120.020545.11.180.1317825.019821.31.320.74N/APendino and colleagues, 1998 \[[@CR2]\]20071.042698.0N/AN/A20968.033773.2N/AN/AFEV1.0, forced expiratory volume in 1 second; N/A, not available; PEFR, peak expiratory flow rate; SD, standard deviation.

Integrating the standardized mean difference in each study, a random effects model showed that inhaled furosemide had a significant positive effect on asthma attacks (*Z* = 2.70; 95% confidence interval, 0.14 to 0.85; *P* = 0.007) with a negligible heterogeneity (*I*^2^ = 16.82) (Figure [2](#Fig2){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}). Subanalyses of the studies reporting the peak expiratory flow rate (*Z* = 2.23; *P* = 0.026; *n* = 68/70, inhaled furosemide/placebo) and the forced expiratory flow in 1 second (*Z* = 1.84; *P* = 0.066; *n* = 49/46, inhaled furosemide/placebo) values confirmed the significant effectiveness of inhaled furosemide for asthma attacks (Table [3](#Tab3){ref-type="table"}). Jackknife sensitivity analyses confirmed the replicability of these findings (*P* \<0.028) (Figure [3](#Fig3){ref-type="fig"}). No adverse events associated with furosemide inhalation were reported.Figure 2**Meta-analysis of randomized clinical trial studies.** A random effects model demonstrated significant effectiveness of inhaled furosemide for asthma attacks \[[@CR1]-[@CR6]\]. CI, confidence interval; Std, standard.Table 3**Meta-analyses of randomized controlled trialsNumber of studiesFurosemide group (** ***n*** **)Placebo group (** ***n*** **)Lower 95% CIUpper 95% CI*Z*** **value*P*** **value*I*** ^***2***^Whole studies678790.140.852.700.00716.8PEFR568700.0580.902.230.02630.4FEV1.034946--0.0270.831.840.0668.16CI, confidence interval; FEV1.0, forced expiratory volume in 1 second; PEFR, peak expiratory flow rate.Figure 3**Jackknife sensitivity analysis, excluding one study at a time.** All sensitivity analyses preserved the significant effectiveness of inhaled furosemide for asthma attacks \[[@CR1]-[@CR6]\]. CI, confidence interval; Std, standard.

These results thus reveal a statistically significant improvement in airflow obstruction with no evident adverse events when inhaled furosemide was used as an adjunctive treatment for acute asthma exacerbation. The present study provides evidence supporting the addition of inhaled furosemide to conventional treatment in clinical situations.
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